Search Results
Your search for ,foR matches 32723 pages
Showing 31601 - 31650MET Immunohistochemistry Expression Is Best Predictor of Benefit From Addition of Onartuzumab to Erlotinib in Advanced NSCLC
A recent phase II study showed progression-free survival and overall survival benefits with the addition of onartuzumab (an antibody directed against MET, a receptor kinase that binds hepatocyte growth factor [HGF]) to erlotinib (Tarceva) in the subset of patients with advanced non–small cell ...
Bendamustine/Rituximab May Be Important Alternative Treatment Option for Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
Results from the BRIGHT study combined with long-term safety data from other studies suggest that bendamustine (Treanda) plus rituximab (Rituxan) “may be an important alternative treatment option” for the initial therapy of patients with low-grade non-Hodgkin lymphoma (NHL) and mantle...
Digital Mammography Reduces Recall and Biopsy Rates
Population-based screening with full-field digital mammography is associated with lower recall and biopsy rates than screen-film mammography, suggesting that full-field digital mammography may reduce the number of diagnostic workups and biopsies that do not lead to diagnosis of breast cancer,...
Obesity Primes the Colon for Cancer, According to NIH Study
Obesity, rather than diet, causes changes in the colon that may lead to colorectal cancer, according to a study in mice by the National Institutes of Health. The finding bolsters the recommendation that calorie control and frequent exercise are not only key to a healthy lifestyle, but a strategy to ...
Patient Characteristics and Outcome Differ in Clinical Trial vs General Population Elderly Patients With Hormone Receptor–Positive Breast Cancer
In a study reported in the Journal of the National Cancer Institute, van de Water et al found that Dutch women with hormone receptor–positive breast cancer aged ≥ 65 years at diagnosis who were treated in a clinical trial had significantly fewer comorbid diseases, higher socioeconomic...
Radiofrequency Ablation Reduces Risk of High-Grade Dysplasia and Adenocarcinoma vs Endoscopic Surveillance in Patients With Barrett’s Esophagus
Barrett’s esophagus with low-grade dysplasia increases risk of esophageal adenocarcinoma. In a European study reported in JAMA, Phoa et al assessed whether endoscopic radiofrequency ablation reduced the rate of neoplastic progression compared with endoscopic surveillance in patients with...
Three-Dimensional MRI Scans May Offer More Accurate Way to Predict Survival After Chemotherapy for Liver Tumors
In a series of studies involving 140 American men and women with liver tumors, researchers at Johns Hopkins have used specialized three-dimensional (3D) MRI scans to precisely measure living and dying tumor tissue to quickly show whether highly toxic chemotherapy is working. The investigators said ...
Study Finds Chemotherapy Accelerates Molecular Aging in Patients With Breast Cancer
Physicians have long suspected that chemotherapy can accelerate the aging process in patients treated for cancer. Using a test developed at UNC Lineberger Comprehensive Cancer Center to determine molecular aging, oncologists have directly measured the impact of anticancer chemotherapy drugs on...
Women Are Infrequently First or Corresponding Authors in Collaborative Group Publications in Oncology
As reported in a research letter in JAMA Internal Medicine, Sun et al studied the frequency with which women lead clinical trial publications from organized collaborative groups in oncology. They found that women are very infrequently lead or corresponding authors, with the percentages not changing ...
Phase II Trial Shows Feasibility of Customized Adjuvant Treatment in NSCLC, but Phase III Trial Canceled Due to Unreliability of ERCC1 Readouts
In the phase II Tailored Postsurgical Therapy in Early-Stage NSCLC (TASTE) trial (IFCT-0801), reported in the Journal of Clinical Oncology, Wislez et al examined the feasibility of customized adjuvant treatment based on EGFR mutation status and expression of ERCC1 (excision repair...
DNA Test Can Help Predict Bladder Cancer Recurrence
A DNA methylation marker test performed on patients with noninvasive urothelial carcinoma can predict tumor recurrence with high sensitivity and specificity, according to a study by Su et al. The findings may help eliminate costly and unnecessary invasive exams and reveals the importance of DNA...
Anastrozole Reduces Breast Cancer Incidence in High-Risk Postmenopausal Women
In the phase III IBIS-II trial, reported in The Lancet, Cuzick et al found that aromatase inhibitor therapy with anastrozole reduced risk of breast cancer in postmenopausal women at high risk of the disease. Study Details In this double-blind trial, 3,864 postmenopausal women aged 40 to 70 years...
Experts Call for More Awareness of Sexual Dysfunction in Lung Cancer Patients
Many lung cancer patients suffer difficulties with sexual expression and intimacy, yet for too long the topic has been ignored by doctors and researchers, experts said at the 4th European Lung Cancer Conference (ELCC) in Geneva, Switzerland. Researchers have estimated that sexual dysfunction...
FDA Panel Endorses Stool-Based DNA Colon Cancer Test
The U.S. Food and Drug Administration’s (FDA) committee of genetic experts has determined that Cologuard, a stool-based DNA, noninvasive screening test for colorectal cancer, has demonstrated safety, effectiveness, and a favorable risk-benefit profile. The FDA is now considering the...
Ceritinib Highly Active in Patients With ALK-Rearranged Advanced NSCLC, Including Those With Prior Crizotinib Treatment
Non–small cell lung cancer (NSCLC) harboring ALK rearrangement is sensitive to the ALK inhibitor crizotinib (Xalkori), but resistance ultimately occurs. In a phase I study reported in The New England Journal of Medicine, Shaw et al found that the more-potent ALK inhibitor ceritinib was...
Metastatic Neuroblastoma Confined to Distant Lymph Nodes Associated With Better Survival Compared With Other Stage IV Disease
The pattern of metastatic spread is not incorporated into current risk-stratification systems for neuroblastoma. In a retrospective study reported in the Journal of Clinical Oncology, Morgenstern et al found that patients with neuroblastoma with metastatic disease limited to distant lymph nodes...
Long-Term Benefit With Dasatinib After Imatinib Failure in Chronic-Phase CML
Patients with chronic myeloid leukemia (CML) in the chronic phase who are resistant or intolerant to imatinib (Gleevec) can experience long-term benefit with dasatinib (Sprycel), according to results of a randomized phase III study. The CA180-034 study also found that early molecular and...
Gene Implicated in Progression and Relapse of Triple-Negative Breast Cancer
Scientists from Weill Cornell Medical College, New York, and Houston Methodist, Houston, have found that a gene previously unassociated with breast cancer plays a pivotal role in the growth and progression of the triple-negative form of the disease. The research by Chen et al, published in Nature,...
Prolonged Administration of Azacitidine Improves Response in Myelodysplasia, Less So in Combination With Entinostat
In the phase II US Leukemia Intergroup Trial E1905 reported in the Journal of Clinical Oncology, Prebet et al found that prolonged administration of lower-dose azacitidine produced a high response rate in patients with myelodysplastic syndrome or acute myeloid leukemia (AML) with myelodysplastic...
Pemetrexed and Gemcitabine Show Promise Against Aggressive Childhood Brain Tumor
The quest to improve survival of children with a high-risk brain tumor has led investigators at St. Jude Children's Research Hospital to two drugs already used to treat adults with breast, pancreatic, lung, and other cancers. The study by Morfouace at al was published today in Cancer Cell....
Tumor Size, Location, and Mitotic Rate, but Not Genotype, Associated With Recurrence-Free Survival in Trial of Adjuvant Imatinib vs Placebo in GIST
The ACOSOG Z9001 (Alliance) study showed that 1 year of adjuvant imatinib (Gleevec) prolonged recurrence-free survival after resection of primary gastrointestinal stromal tumors (GIST). As reported by Corless et al in the Journal of Clinical Oncology, a study evaluating correlation of pathologic...
Continued Event-Free Survival Benefit of Neoadjuvant/Adjuvant Trastuzumab in HER2-Positive Locally Advanced Breast Cancer
As reported by Gianni et al in The Lancet Oncology, long-term follow-up of women with HER2-positive locally advanced breast cancer receiving neoadjuvant chemotherapy alone vs with neoadjuvant and adjuvant trastuzumab (Herceptin) in the phase III NOAH trial has shown continued event-free survival...
Electronic Cigarette Usage Associated With Use of Conventional Cigarettes Among Adolescents
“Use of e-cigarettes does not discourage, and may encourage, conventional cigarette use among US adolescents.” This was the conclusion of a cross-sectional analysis of survey data from a representative sample of middle and high school students who completed the National Youth Tobacco...
Immunotherapy Data Herald New Era of Lung Cancer Treatment
A new era of lung cancer therapy is dawning, using drugs that can prevent tumor cells from evading the immune system, experts reported at the 4th European Lung Cancer Congress. For decades, scientists and doctors thought immunotherapy was of marginal benefit in lung cancer, said ESMO spokesperson...
Omitting Radiotherapy in Early PET-Negative Stage I/II Hodgkin Lymphoma Is Associated With Increased Risk of Early Relapse
The EORTC/LYSA/FIL Intergroup H10 trial assessed whether omitting involved-node radiotherapy would affect progression-free survival in patients with negative early positron-emission tomography (PET) scans after two cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) compared with...
Erlotinib and Gefitinib Offer Similar Benefit in EGFR-Mutated Non–Small Cell Lung Cancer
A retrospective study has shown that two targeted therapy drugs—erlotinib (Tarceva) and gefitinib (Iressa)—achieved similar outcomes among people with metastatic or recurrent non–small cell lung cancer (NSCLC) harboring an EGFR mutation. These EGFR tyrosine kinase inhibitors have...
Phase III Study: Crizotinib Prolongs Progression-Free Survival in Previously Untreated ALK-Positive Advanced NSCLC
In the phase III PROFILE 1014 study, the anaplastic lymphoma kinase (ALK) inhibitor crizotinib (Xalkori) was found to significantly prolong progression-free survival in previously untreated patients with ALK-positive advanced nonsquamous non–small cell lung cancer (NSCLC) compared with...
Locoregional Progression of Cervical Cancer Follows Reverse Ontogenetic Sequence
In a study reported in The Lancet Oncology, Höckel et al demonstrated that locoregional progression of cervical cancer follows the reverse sequence of establishment of adult tissues in ontogeny. Ontogenetic staging was a better predictor of survival than pathologic staging. Previous work by...
Phase II Study Suggests Benefit of Adding Rituximab to Chlorambucil in First-Line Treatment for Chronic Lymphocytic Leukemia
In a UK phase II study reported in the Journal of Clinical Oncology, Hillmen et al assessed the safety and activity of adding rituximab (Rituxan) to chlorambucil (Leukeran) in first-line treatment of chronic lymphocytic leukemia (CLL). Such a regimen may be an alternative to fludarabine-based...
PARP Inhibitor Veliparib Might Benefit Women With Resistant Gynecologic Cancers and BRCA Mutation
Preliminary research suggests that a targeted oral agent may improve outcomes while minimizing side effects in women with gynecologic cancers who carry a BRCA mutation and whose disease is not responding to other therapies. According to a phase II study presented at the Society of Gynecologic...
Lymphedema Lingers Long After Sentinel Lymph Node Dissection for Early Breast Cancer
Patients with early-stage breast cancer who underwent sentinel lymph node dissection experienced lymphedema more frequently than clinically suspected and with increasing incidence over time, according to a presentation at the 2014 Society of Surgical Oncology (SSO) Cancer Symposium in Phoenix...
Long-Term Use of Valproic Acid May Reduce the Risk of Head and Neck Cancer
The antiseizure medication and mood stabilizer valproic acid was associated with a significant reduction in head and neck cancer risk, according to a study recently published in Cancer. The large retrospective cohort study by Kang et al was conducted to evaluate the effects of the drug, a histone...
Long-Term Follow-up Shows Surgery Plus Radiation Offers Mixed Results in Soft-Tissue Sarcoma
Adjuvant radiation following surgery for soft-tissue sarcoma of the extremities did not lead to a survival benefit and seemed to be associated with some degree of long-term limb complications, according to a presentation at the 2014 Society of Surgical Oncology (SSO) Cancer Symposium in Phoenix...
Stool Multitarget DNA Test More Sensitive, But Less Specific Than Fecal Immunochemical Test for Colorectal Cancer Screening in Persons at Average Risk
In a study reported in The New England Journal of Medicine, Imperiale et al found that a noninvasive, multitarget stool DNA test—including assays for KRAS mutations, aberrant NDRG4 and BMP3 methylation, β-actin, and hemoglobin—was significantly more sensitive but significantly less ...
Study Finds Oncologists Have Mixed Attitudes on the Use of Genomic Testing
While many cancer researchers believe that predictive somatic genomic testing holds the potential to usher in the era of precision medicine for patients with cancer, research by Gray et al suggests that not all physicians are eager to embrace the technology. The variation in attitudes was in part...
Risk Factors for Gastrointestinal Adverse Events Studied in Setting of First-Line Bevacizumab/Chemotherapy for Ovarian Cancer
As reported in the Journal of Clinical Oncology, Burger et al assessed risk factors for gastrointestinal adverse events in women with advanced ovarian cancer receiving first-line bevacizumab (Avastin)/chemotherapy with or without bevacizumab maintenance or chemotherapy alone in the phase III...
Women With Gynecologic Cancers May Live Longer When Treated at High-Volume Medical Centers
Women with ovarian and other gynecologic cancers live significantly longer when they receive care at hospitals that treat a large number of patients with these conditions, according to research on more than 850,000 women. The findings, based on information from the nation’s largest cancer...
Women With BRCA1 Mutations May Still Be at Risk for Rare Types of Uterine Cancer After Preventive Salpingo-Oophrectomy
Women with BRCA1 mutations may have an increased risk for developing rare types of aggressive uterine cancer despite having their ovaries and fallopian tubes removed, suggest preliminary findings presented at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer held ...
Bariatric Surgery May Lower Risk of Uterine Cancer
Women who had bariatric surgery to lose weight had a 70% lower risk of uterine cancer and an even lower risk if they kept the weight off, according to findings presented at the Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer, held in Tampa, Florida, from March 22 to 25. ...
Audit of NHS Breast Cancer Screening Programme Reveals Significant Variations Between Hospitals in Treatment Outcomes for DCIS
Analysis of data from the UK NHS Breast Screening Programme has shown significant variations in the outcomes of treatment for women with ductal carcinoma in situ (DCIS) between UK hospitals. Dr. Jeremy Thomas, a consultant pathologist at the Western General Hospital, Edinburgh, told the 9th...
ASCO Issues Updated Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer
A review by ASCO’s Update Committee of new data from randomized clinical trials has led to a change in recommendations for the use of sentinel lymph node biopsy in patients with early-stage breast cancer. The updated guideline will enable more women with early-stage breast cancer to avoid the ...
Harms Outweigh Benefits for Women Aged 70 and Over in National Breast Cancer Screening Programs
Extending national breast cancer screening programs to women over the age of 70 does not result in a decrease in the number of cancers detected at advanced stages, according to new research from The Netherlands. Instead, researchers told attendees at the 9th European Breast Cancer Conference that...
Investigational Cancer Vaccine Shows Renewed Potential in Non–Small Cell Lung Cancer
Researchers at UC Davis have found that the investigational cancer vaccine tecemotide, when administered with the chemotherapeutic agent cisplatin, boosted immune response and reduced the number of tumors in mice with lung cancer. The study also found that radiation treatments did not...
Obesity and Diabetes Have Adverse Effects on Outcomes Across Breast Tumor Types, Should Be Taken Into Account When Planning Treatment
Both obesity and diabetes have adverse effects on outcomes in breast cancer patients who receive neoadjuvant chemotherapy, according to research presented at the 9th European Breast Cancer Conference. Although a high body mass index (BMI) is known to have a negative impact on cancer development and ...
Socioeconomic Disparities in Mortality After Cancer Surgery Reflect Higher Failure-to-Rescue Rates in Hospitals Treating More Low-Income Patients
Although it has been found that lower socioeconomic status is associated with higher operative mortality, the factors explaining this disparity have not been clearly defined. In a study of major cancer surgery reported in JAMA Surgery, Reames et al found that hospitals with the highest proportion...
Preclinical Study Suggests Benefits of Increased Tumor Perfusion and Reduced Tumor Hypoxia With Exercise in Prostate Cancer
In a study reported in the Journal of the National Cancer Institute, McCullough et al used an orthotopic rat model of prostate cancer to assess the effects of exercise on tumor hemodynamics and tissue hypoxia. Their findings of enhanced tumor perfusion and diminished tumor hypoxia suggest that...
Analysis of SWOG Trials Indicates No Survival Difference After 1 Year in Cancer Patients Treated In vs Out of Clinical Trials
In a study reported in the Journal of the National Cancer Institute, Unger et al evaluated whether cancer patients from SWOG clinical trials were similar to nontrial patients in baseline characteristics and survival. They found that, overall, trial participation in standard treatment arms did not...
Regular Physical Activity Reduces Breast Cancer Risk Irrespective of Age or Weight
Participating in athletic activities for more than an hour a day reduces the risk of breast cancer, and this applies to women of any age and any weight, regardless of geographic location, according to research presented at the 9th European Breast Cancer Conference in Glasgow. Compared with the...
Genetic Testing May Improve Selection of Women With Estrogen Receptor–Positive Breast Cancer for 10 vs 5 Years of Hormonal Therapy
Genetic analyses of results from 1,125 postmenopausal women being treated for estrogen-responsive breast cancer have shown that some of them are more likely than others to have a late recurrence of their cancer and might benefit from 10 years of hormone therapy rather than 5 years. Women who had...
Postmastectomy Radiotherapy Benefits Women With Breast Cancer That Has Spread to One to Three Lymph Nodes
Women whose breast cancer has spread to just a few lymph nodes under their arm are less likely to have their disease recur or to die from it if they have radiotherapy after mastectomy, according to new research presented today at the European Breast Cancer Conference in Glasgow and published in The ...
